3 June 2025 · 1 min read
The FDA now uses GenAI to review your dossier - and that's a good thing.
The FDA is now using GenAI to review regulatory dossiers — and I think that's a good thing. Pharma companies have already been using generative AI to craft submissions, so it makes perfect sense for regulators to leverage the same technology on their end.
Filed under AI in Pharma
The FDA now uses GenAI to review your dossier - and that's a good thing.
Why? Because pharma companies have already been harnessing generative AI to craft clinical trial designs, draft protocols, and streamline regulatory submissions. It makes perfect sense that regulatory authorities leverage similar tech for review processes, ensuring alignment and efficiency.
Now, with the FDA integrating its own AI, we're entering a fascinating new era: where AI-optimized submissions meet AI-powered reviews. Watching how this dynamic evolves in the coming years will be very interesting.
Related insights
9 Oct 2024
A great talk from Gilead's Jeremy Zhang on scaling LLMs like OpenAI and Claude to the clinical po...
18 Jun 2025
An interesting discussion on AI in drug discovery and development with Thirupathi Pattipaka from...
28 May 2026
Do not get out of bed for an AI project worth less than $100 million.
12 May 2026
Isomorphic about to raise $2bn - and why I'm not sure that's a good thing